Recent Highlights and Accomplishments
-- More than 10,220 test results delivered in the third quarter of 2008,
compared with more than 5,950 test results delivered in the third
quarter of 2007, an increase of 72 percent year-over-year.
-- More than 75,000 Oncotype DX test results have been delivered to
-- Gained coverage for an additional 7.9 million lives for reimbursement
of Oncotype DX through contracts, policies and agreements, bringing the
total U.S. covered lives to approximately 89 percent of insured lives
including: Coventry Health Care (4.4 million lives), Blue Cross and
Blue Shield of Massachusetts (1.3 million lives), Medica Health Plans,
HMSA Blue Cross Blue Shield of Hawaii, and WPS Health Insurance in
-- Named a Vice President to oversee European markets.
-- Established distribution agreements in Australia and Taiwan.
-- Received test samples from 39 countries to date.
-- Oncotype DX included in the updated 2008 guidelines of the Dutch
Institute for Healthcare Improvement.
-- Enhanced clinical utility of Oncotype DX reports by including
quantitative HER2 scores; quantitative estrogen receptor and
progesterone receptor scores were added earlier this year.
-- Completed European study using Oncotype DX in node-negative and
node-positive, breast cancer patients treated with aromatase
inhibitors, which was accepted for oral presentation at the San Antonio
Breast Cancer Symposium in December 2008.
-- Continued to make progress toward a clinical validation
|SOURCE Genomic Health, Inc.|
Copyright©2008 PR Newswire.
All rights reserved